Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
The personalized mRNA vaccine against melanoma — the deadliest form of skin cancer — reduced the risk of death or recurrence by 42 percent compared with standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday. The companies said they are already engaging with regulatory authorities to get the vaccine approved, and Moderna CEO Stéphane Bancel said the company had long believed mRNA technology could make cancer treatments uniquely matched to each patient's tumor. It matters because the success bolsters hope that mRNA vaccines and individualized cancer-targeting medicines could offer a new paradigm for cancer therapies — a potential defining moment for the field.
SOURCES
- Ars Technica2026-10-22 22:12